News | Radiopharmaceuticals and Tracers | June 20, 2016

Pretargeted Radioimmunotherapy May Eliminate Colorectal Cancer

Antibody and radionuclide drug combo provides a cure in preclinical colorectal cancer research

pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

June 20, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.

Theranostic drugs are powerful newcomers in oncology’s arsenal. In addition to providing targeted treatment, in many cases they double as imaging agents that can monitor the effectiveness of therapy.

An investigative treatment called pretargeted radioimmunotherapy (PRIT) is harnessing an antibody that attaches to the cell-surface antigen glycoprotein A33, which is hyper-expressed in the vast majority of colon cancers, whether primary or metastatic. Researchers united the anti-GPA33 antibody with radionuclide agents that deliver a powerful dose of radiation directly to the tumor. The technique was found to be entirely curative in this preliminary mouse study.

“If these results can be replicated in prospective human studies, this multi-platform approach could be used with an array of antibodies to treat a number of cancers, especially colorectal and ovarian cancers,” said Sarah M. Cheal, Ph.D., the presenting author from Memorial Sloan Kettering Cancer Center, New York, N.Y.

For this study, researchers tested the efficacy of anti-GPA33 with radiotherapies using lutetium-177 benzylDOTA (Lu-177 DOTA-Bn) in mice bearing colorectal cancer grafts. In the same group of animals, the researchers were able to detect solid tumors of 10 milligrams or less during the course of a fractionated treatment regimen that achieved complete cures in all solid tumors without any collateral toxicity. This platform of theranostic radioimmunotherapy could have broad applicability. Cheal estimates that, if validated, these cancer-fighting techniques could be made available in as few as five years.

According to the most current statistics from the American Cancer Society, an estimated 71,830 American men and 65,000 women will be diagnosed with colorectal cancer in 2016. Approximately 26,270 men and 24,040 women are expected to die from the disease.

For more information: www.snmmi.org

Related Content

El Camino Hospital to Offer Calypso 4-D Localization System
News | Radiation Therapy | July 21, 2017
El Camino Hospital (Mountain View, Calif.) announced the installation of a new Calypso 4-D Localization System and will...
Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning
News | Treatment Planning | July 21, 2017
RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound | July 20, 2017
In a large, first-of-its-kind population, researchers found an experimental technique known as three-dimensional...
ACR Updates Radiation Oncology and Medical Physics Guidance With ASTRO and AAPM
News | Radiation Dose Management | July 19, 2017
July 19, 2017 — The American College of Radiology (ACR) recently collaborated with professional medical societies to
News | Radiation Therapy | July 19, 2017
July 19, 2017 — The members of the American Society for Radiation Oncology (ASTRO) have elected three new officers to
Glendale Adventist Medical Center Opens Temporary Radiotherapy Vault
News | Radiation Therapy | July 19, 2017
July 19, 2017 — RAD Technology Medical Systems announced their most recent project at Glendale Adventist Medical Cent
IBA to Install Proton Therapy Facility at Inova Schar Cancer Institute
News | Proton Therapy | July 18, 2017
IBA (Ion Beam Applications S.A.) and Inova recently signed a contract for a two-room Proteus Plus proton therapy...
Proton International and Beaumont Health Open Michigan's First Proton Therapy Facility
News | Proton Therapy | July 17, 2017
Proton International (PI) and Beaumont Health recently opened the state’s first proton therapy center, offering the...
Low Doses of Radiation Could Harm Cardiovascular Health
News | Radiation Dose Management | July 17, 2017
Ionizing radiation, such as X-rays, has a harmful effect on the cardiovascular system even at doses equivalent to...
Overlay Init